List view / Grid view
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
30 October 2013 | By AstraZeneca
The goal of CALIMA is to determine whether benralizumab reduces the number of exacerbations in patients with severe asthma that remains uncontrolled...
28 October 2013 | By Dr Kevin Robinson
End-users, be they patients or consumers, are taking a good look at the cardiovascular benefits of omega-3s … and tend to like what they see.
24 October 2013 | By AstraZeneca
The proposal to close the site has been made as the work undertaken at the laboratory is outside the organisation’s strategic focus...
22 October 2013 | By AstraZeneca
SELECT-1 will be the first Phase III study to investigate whether a MEK inhibitor in combination with chemotherapy is superior to chemotherapy alone...
21 October 2013 | By College Hill
Dr Holland is an expert in biomarker-driven drug development...
15 October 2013 | By AstraZeneca
Additional investment in and collaboration with ADC Therapeutics...
11 October 2013 | By AstraZeneca
AstraZeneca announced that it has entered into an agreement to co-promote, an innovative oral therapy for the treatment of patients with prostate cancer...
7 October 2013 | By AstraZeneca
As previously announced, the acquisition bolsters MedImmune’s oncology pipeline...
3 October 2013 | By Amgen
"The Phase 2 data demonstrate that the primary and secondary end points were met..."
2 October 2013 | By AstraZeneca
AstraZeneca announced that the US Court of Appeals for the Federal Circuit (CAFC) lifted a temporary injunction against the US launch of Hanmi's 505(b)2 NDA esomeprazole strontium product...
2 October 2013 | By AstraZeneca
Hanmi’s launch would be at risk of owing AstraZeneca patent-infringement damages...
1 October 2013 | By AstraZeneca
The growth of the BioHub complements the work of the Alderley Park taskforce to capitalise and build on the existing local bioscience network and expertise...
27 September 2013 | By AstraZeneca
AstraZeneca today announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for olaparib...
27 September 2013 | By AstraZeneca
Naloxegol is an investigational peripherally-acting mu-opioid receptor antagonist designed for the treatment of opioid-induced constipation (OIC)...
25 September 2013 | By Bristol-Myers Squibb Company
At 24 weeks in patients with Type 2 diabetes inadequately controlled with the combination of Metformin Plus Sulfonylurea...
